| |
| |
|
| Insider
Information: |
Butler John P. |
| Relationship: |
|
| City: |
Redwood City |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
2,064,580 |
|
|
Indirect Shares
|
319,856 |
|
|
| Direct
Value |
$2,657,954 |
|
|
|
Indirect Value
|
$415,813 |
|
|
| Total
Shares |
2,384,436 |
|
|
| Total
Value |
$3,073,767 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
11
|
|
Stock
price went up :
|
0
|
3
|
| Stock
price went down : |
0
|
8
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -26.2%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Akebia Therapeutics, Inc. |
AKBA |
|
2024-02-29 |
2,044,580 |
2024-02-29 |
319,856 |
Premium* |
|
|
Relypsa Inc |
RLYP |
Director |
2016-09-01 |
0 |
2014-06-19 |
0 |
Premium* |
|
|
Keryx Biopharmaceuticals Inc |
KERX |
Director |
2017-06-09 |
20,000 |
|
0 |
Premium* |
|
|
Zynerba Pharmaceuticals, Inc. |
ZYNE |
|
2023-10-10 |
0 |
2018-08-22 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AKBA |
Akebia Therapeutics, Inc. |
CEO and President |
• • – |
2024-02-29 |
4 |
S |
$1.58 |
$73,581 |
D/D |
(46,570) |
2,044,580 |
0 |
% |
|
| AKBA |
Akebia Therapeutics, Inc. |
CEO and President |
• • – |
2024-02-27 |
4 |
S |
$1.52 |
$57,354 |
D/D |
(37,733) |
2,091,150 |
0 |
% |
|
| AKBA |
Akebia Therapeutics, Inc. |
CEO and President |
• • – |
2024-02-01 |
4 |
S |
$1.68 |
$78,102 |
D/D |
(46,489) |
2,128,883 |
0 |
% |
|
| AKBA |
Akebia Therapeutics, Inc. |
CEO and President |
• • – |
2024-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
603,500 |
2,175,372 |
0 |
- |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
|
• • – |
2023-10-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(80,765) |
0 |
0 |
- |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Director |
– • – |
2023-06-14 |
4 |
S |
$0.35 |
$40 |
D/D |
(115) |
80,765 |
0 |
% |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Director |
– • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
47,824 |
80,880 |
0 |
- |
|
| AKBA |
Akebia Therapeutics, Inc. |
CEO and President |
• • – |
2023-03-01 |
4 |
S |
$0.88 |
$80,614 |
D/D |
(91,868) |
1,568,872 |
0 |
% |
|
| AKBA |
Akebia Therapeutics, Inc. |
CEO and President |
• • – |
2023-02-27 |
4 |
S |
$0.81 |
$31,416 |
D/D |
(38,632) |
1,660,740 |
0 |
% |
|
| AKBA |
Akebia Therapeutics, Inc. |
CEO and President |
• • – |
2023-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
293,125 |
1,699,372 |
0 |
- |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Director |
– • – |
2022-06-14 |
4 |
S |
$1.01 |
$54 |
D/D |
(53) |
33,056 |
0 |
% |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Director |
– • – |
2022-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
23,109 |
33,109 |
0 |
- |
|
| AKBA |
Akebia Therapeutics, Inc. |
CEO and President |
• • – |
2022-03-01 |
4 |
S |
$2.17 |
$117,159 |
D/D |
(53,973) |
1,403,247 |
0 |
% |
|
| AKBA |
Akebia Therapeutics, Inc. |
CEO and President |
• • – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
293,125 |
1,457,220 |
0 |
- |
|
| AKBA |
Akebia Therapeutics, Inc. |
CEO and President |
• • – |
2022-02-28 |
4 |
S |
$2.15 |
$53,984 |
D/D |
(25,053) |
1,164,095 |
0 |
% |
|
| ZYNE |
Zynerba Pharmaceuticals, ... |
Director |
– • – |
2021-08-03 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
10,000 |
0 |
- |
|
| AKBA |
Akebia Therapeutics, Inc. |
CEO and President |
• • – |
2021-04-01 |
4 |
S |
$3.40 |
$13,971 |
D/D |
(4,109) |
1,152,153 |
0 |
% |
|
| AKBA |
Akebia Therapeutics, Inc. |
CEO and President |
• • – |
2021-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
39,520 |
1,156,262 |
0 |
- |
|
| AKBA |
Akebia Therapeutics, Inc. |
CEO and President |
• • – |
2021-03-01 |
4 |
S |
$3.40 |
$169,771 |
D/D |
(49,990) |
1,116,742 |
0 |
% |
|
| AKBA |
Akebia Therapeutics, Inc. |
CEO and President |
• • – |
2021-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
237,400 |
1,166,732 |
0 |
- |
|
| AKBA |
Akebia Therapeutics, Inc. |
CEO and President |
• • – |
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
237,400 |
1,026,632 |
0 |
- |
|
| AKBA |
Akebia Therapeutics, Inc. |
CEO and President |
• • – |
2019-06-03 |
4 |
OE |
$0.47 |
$134,890 |
D/D |
287,000 |
836,232 |
0 |
- |
|
| AKBA |
Akebia Therapeutics, Inc. |
CEO and President |
• • – |
2019-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
239,500 |
614,382 |
0 |
- |
|
| AKBA |
Akebia Therapeutics, Inc. |
CEO & President |
• • – |
2018-12-12 |
4 |
D |
$8.94 |
$1,213,131 |
D/D |
(135,697) |
374,617 |
0 |
- |
|
| AKBA |
Akebia Therapeutics, Inc. |
CEO and President |
• • – |
2018-12-12 |
4/A |
A |
$0.00 |
$0 |
D/D |
1,248 |
375,865 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
